The human homologue of the mouse double minute 2 (MDM2) oncogene is overexpressed in more than forty different types of malignancies, including solid tumors, sarcomas and leukemias. Because of its prevalent expression and its interactions with p53 and other signaling molecules, MDM2 plays a central role in cancer development and progression. The expression of this oncoprotein is being studied by researchers world-wide, and the amount of data published about it is increasing exponentially. Although there are some conflicting data about the effects of MDM2 expression in individual cancers, the overall evidence is convincing, indicating that increased MDM2 expression is related to a worse clinical prognosis. There is an increased likelihood of distant metastases, as well as a decreased response to therapeutic intervention in MDM2-positive cancers. MDM2 may also serve as a diagnostic marker, not only for cancer stage, but to differentiate between similar cancers. MDM2 may also be associated with drug resistance in cancer chemotherapy. These findings make studying the oncoprotein necessary to aid in our understanding of cancer development, to identify novel cancer drug targets, and to increase the efficacy of cancer therapy.
INTRODUCTION
its functions. Expression of MDM2 is associated with cell cycle progression and apoptosis [5] [6] , and because of its role in these processes, the expression level of MDM2 affects tumorigenesis, likely at several stages of tumor development ( Fig. ( 1) ).
The MDM2 oncogene (the human homologue is also known as HDM2) was originally shown to confer tumorigenicity to NIH3T3 cells in nude mice [1] . In the thirteen years since this discovery, the role that MDM2 plays has been partially uncovered, but with each new discovery, its involvement in normal and tumorigenic cell function has been revealed to be more complex. In early studies, the role of MDM2 in regulating p53 functions was emphasized. However, there is increasing evidence supporting the notion that MDM2 has multiple p53-independent activities. Many efforts have concerned the validation of MDM2 as a prognostic marker and as a novel drug target, and several MDM2 inhibitors have entered preclinical trials [2] . Other articles within this issue of Current Cancer Drug Targets cover, in depth, the discovery and activities of MDM2, including its interactions with p53 and other molecules. This review will focus on the clinical implications of MDM2 expression.
Overexpression of MDM2, seen in a variety of tumors of diverse tissue origins, can result from gene amplification, increased transcription, or enhanced translation [2] . Additionally, changes in stability and activity can be brought about by mutations, splice variations or possibly gene translocations. As for mutations, it was recently found that a single nucleotide polymorphism in the MDM2 intronic promoter (T309G in the first intron) can result in an increase in MDM2 RNA and protein. This mutation apparently causes an increase in the Sp1 transcription factor binding affinity for the MDM2 promoter, thus increasing the rate of MDM2 transcription. As a consequence, the degradation of p53 is enhanced, resulting in a decreased response to DNA damaging agents and an acceleration in tumorigenesis of both sporadic and hereditary cancers [7] .
EXPRESSION OF MDM2 IN HUMAN MALIGNANCIES
Nearly every major cancer type has been evaluated for MDM2 expression; the results are summarized in Table 1 . MDM2 is overexpressed in most cancers, with an overall frequency of gene amplification of 7% [2, 8] . Since early reviews have covered studies accomplished before 2000 [2, 8] , in this article, we will pay more attention to recent reports. Among tumors with MDM2 overexpression, soft tissue sarcomas (STS) have the highest levels of MDM2 protein, mRNA and gene amplification [2, [8] [9] [10] . The MDM2 protein overexpression ranges from 8% of various sarcomas [9] to 68% of angiosarcoma samples [10] . Within the soft tissue sarcomas, liposarcomas have the highest percent of positive staining within tumor samples, with 50% to 56% of the tumors interacting with an antibody against MDM2 [11] [12] [13] . Osteosarcomas exhibit strong staining, MDM2 is ubiquitously expressed, although the expression level varies with cell type and conditions [3] . The protein is required for basic cell functions, and mice with MDM2 knocked-out die during embryonic development or shortly after birth [4] . But mice with gene knockouts for both MDM2 and p53 survive, indicating that MDM2 has a critical role in regulating the level of p53 and ranging from less than 10% to over 55% [13] [14] [15] . Many of these and other studies found amplified gene or mRNA overexpression. For example, the study that found 56% of osteosarcomas overexpressed MDM2 protein also found MDM2 gene amplification in 67% of the samples [15] . MDM2 is overexpressed in more than 40% of testicular and intracranial germ cell tumor samples [16] [17] [18] , and 93% of embryonic carcinomas [17] . Gene amplification was observed in 12% of samples in a study of testicular germ cell tumors, and in 19% of samples in a study of intracranial germ cell tumors [18, 19] .
Various types of carcinomas have increased expression of the MDM2 protein, its mRNA and its gene. Bladder carcinomas, which have been well studied, display positive staining for MDM2 in 12% to 49% of tumors [21, [42] [43] [44] [45] [46] . Fewer studies have looked at gene amplification or overexpression of mRNA in bladder cancer, but both gene and mRNA expression are elevated [43, 47] . Several groups have looked for MDM2 expression in breast carcinoma. Up to 54% positive staining was seen by one group [48] , and gene amplification was observed in 4% to 61% of tumor samples [49] [50] [51] [52] [53] [54] [55] . Similarly, up to 65% of colorectal carcinomas stained positively for MDM2 [56] [57] [58] . Esophageal squamous cell carcinomas had staining in about the same range [59, 60] and gene amplification in approximately 20% of tumor samples [61, 62] . Non-small cell lung cancer, prostate, and ovarian cancers have increased expression of MDM2 [2, 8] . A number of other malignancies, such as Wilm's tumors, melanoma, nasopharyngeal, head and neck, cervical, pancreatic, hepatic, and thyroid cancers have been examined, but in only a few studies, or with only a small number of patient samples, making it difficult to evaluate whether MDM2 is elevated in these cancers.
Often noted for overexpression of MDM2 are brain and hematological malignancies. Glioblastomas and astrocytomas show positive staining for MDM2 protein in up to 75% of tumor samples, and approximately 10% of samples have gene amplification [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . Hematological malignancies typically have high MDM2 expression as well. Acute lymphocytic leukemia (ALL) has more than 10-fold overexpression of MDM2 protein in more than 29% of samples [30, 31] . Other types of leukemia also overexpress MDM2, with 59%, 64% and 47% in studies of various leukemias, chronic lymphocytic leukemia (CLL) and acute myelocytic leukemia (AML), respectively, expressing the protein [32] [33] [34] . Both Burkitt's and non-Hodgkin's lymphomas have high expression of MDM2, with 30% to 80% of samples staining positive [35] [36] [37] [38] [39] [40] . Gene amplification is also observed in at least 28% of samples, and mRNA is overexpressed 2-15-fold in 87% of samples [35, 39, 41] .
MDM2 EXPRESSION AS A PROGNOSTIC MARKER
Despite many publications exploring the expression level, functions and interactions of MDM2, there is still not a clear-cut picture of what the presence of this protein means [193] Osteosarcoma (jaw) 56% 67% n/a 9 [14] Osteosarcoma 36%-50% n/a 36 [188] ( Multiple myeloma 58% 0% n/a 48 [160] for cancer patients, with respect to diagnosis and prognosis. It is apparent that different cancers behave differently, and the effects of MDM2 likewise are variable. Due to the ubiquitous nature of MDM2 and its involvement in various signaling pathways, some of the results obtained about the effects of MDM2 expression are paradoxical. Perhaps most illustrative of these differences are the soft tissue sarcomas (STS). While all studies show that the sarcomas overexpress MDM2, there are conflicting reports as to the effect of MDM2 expression on prognosis. There have been several studies indicating that MDM2 overexpression correlates with a worse prognosis [63] [64] [65] . One report found that MDM2 was associated with heightened proliferation in the tumor [63] while another found that survival was poorer in patients with cooverexpression of p53 and MDM2 [64] . Ladanyi and coworkers noted that MDM2 overexpression was associated with advanced-stage tumors [65] . Another group found that MDM2 was associated with an increase in expression of vascular endothelial growth factor (VEGF), which is known to promote tumor growth and metastasis [10, [66] [67] [68] . On the other hand, there have been reports that MDM2 expression can be related to a better prognosis [69] , and, in contrast to the findings of Ladanyi et al. is more frequently observed in better-differentiated and lower-grade tumors [13, 70, 71] . A number of studies did not search for a correlation between MDM2 expression and outcome, and several studies of soft tissue sarcomas found no correlation between MDM2 and overall survival, tumor grade or tumor origin [72, 73] .
more easily treated and have better response rates than hormone-independent cancers. In accord with this, exposure of breast cancer cells in vitro to tamoxifen or a protein kinase C inhibitor resulted in decreased MDM2 expression [80] . Similar to reports on other cancers, several studies have found that MDM2 expression is predictive for worse clinical outcome and decreased survival in breast cancer patients [50, 54, 81] . Different isoforms of MDM2 are associated with different grades of tumors, suggesting that it may be necessary to determine which specific isoforms are being expressed before an outcome can be predicted [48] .
In other types of cancer, expression of MDM2 is clearly linked to a worse outcome for patients. In hematological malignancies, including ALL, AML, CLL, non-Hodgkin's and Burkitt's lymphomas, high levels of MDM2 expression correlate with a variety of worse prognostic indications. MDM2 overexpression is related to an increased risk for relapse and decreased remission, while protein expression is typically decreased or absent during remission [30, 31, 34, 74, 75] . Expression of the oncoprotein is also associated with an increased need for bone marrow transplantation and a decreased response to chemotherapy [30, 36, 74] . In nonHodgkin's lymphoma, increased MDM2 expression is associated with higher grade tumors, tumors with diffuse follicle centers, and chromosomal abnormalities, which indicate an advanced disease state and reduced survival [37] [38] [39] 76] . Only one study found that MDM2 was more often increased in low-grade than intermediate or high-grade disease, which could correlate with a better prognosis [41] .
Although only a few studies have been accomplished, expression of MDM2 in prostate cancer seems to be an indicator for worse prognosis. One group found that overexpression of the oncoprotein is associated with advanced stage disease, whereas another found that tumors expressing the protein have a higher proliferation index and larger tumor volume [82, 83] . Similarly, in testicular germ cell cancers, MDM2 expression is increased in more advanced stages of disease (IIB, IIC and III) and correlates with increased invasiveness [16, 17] . Although there have been fewer studies than with the hematological malignancies, survival of patients with esophageal squamous cell carcinoma appears to be negatively affected by MDM2 expression. Two studies found that amplification of the MDM2 gene or overexpression of the protein correlates with a worse prognosis and shorter survival [61, 77] . Another study found that MDM2 expression leads to a decreased response to chemotherapy [60] .
EFFECTS OF MDM2 EXPRESSION ON METASTASIS
Several studies have demonstrated that overexpression of MDM2 is associated with increased metastasis. Examination of 100 samples of esophageal squamous cell carcinoma found that MDM2 expression was the most significant risk factor for distant metastasis [84] . Another found that MDM2 splice variants analyzed in 60 breast cancer samples generally were associated with more aggressive cancer and more frequent involvement of axillary lymph nodes [85] . A recent report proposes a mechanism for the increase in metastasis. Hypoxia, which is common in many tumors, up-regulates MDM2 in a p53-independent manner. This overexpression leads to an increased metastatic efficiency in cell lines, perhaps by rendering tumor cells less sensitive to stressinduced cell death [86] . Additionally, MDM2 increases levels of VEGF [10] , which facilitates extravasation of tumor cells and can lead to growth of distant metastases [66] [67] [68] . MDM2 expression also increases basement membrane degradation in urothelial carcinoma [87] , allowing the cancer to spread. Thus, MDM2 expression increases the risk of distant metastasis, contributing to the overall poorer prognosis for cancers expressing MDM2. However, the role of MDM2 in cancer metastasis and its underlying mechanisms are not fully understood, and more investigations with larger sample sizes and longer durations of follow-up are needed.
Like STS, malignancies of the brain show more diverse outcomes for patients with MDM2-positive tumors. The tendency is toward a worse prognosis, with both an increase in MDM2 expression in short-term survivors (versus longterm) and shorter post-operative survival [22, 25, 27, 28] . One of these studies noted that overexpression of MDM2 correlated with decreased survival in women [22] . Of note, several of the studies where MDM2 expression was found did not evaluate the outcome for patients, while in others there was no statistical difference in survival between patients with normal MDM2 expression and patients overexpressing the oncoprotein [23, 24, 29] . In one examination of patients with glioblastoma multiforme, there was a difference in gene expression between primary and secondary tumors [26] . As with STS, however, there still were a few studies which found that MDM2 expression correlated with a better prognosis, or with less advanced disease [20] .
Bladder carcinoma follows this trend, with most of the studies finding a correlation between MDM2 expression and worse prognosis. One research group noted that MDM2 overexpression correlated with increased grade of tumors and was an indicator for future recurrence [78] . Another group corroborated this with a finding of increased expression of MDM2 in advanced stages of disease [21] . However, one group was unable to find any statistical correlation between MDM2 expression and disease stage or patient survival [45] , presumably due to a small sample size.
MDM2 EXPRESSION AND RESPONSE TO THERAPY
As a negative regulator of p53, MDM2 influences the cellular response to cytotoxic/DNA damaging treatments. In many cell lines and several tumor samples, overexpression of MDM2 typically correlates with a decreased response to both chemotherapy and radiation therapy. For example, in one study using rhabdomyosarcoma cell lines, transfection of MDM2 led to increases up to 61-fold in resistance to vincristine, etoposide and doxorubicin, although it did not For patients with breast carcinomas, MDM2 expression may be related to the hormone status of the tumor. Hori and colleagues found that MDM2 expression correlated with estrogen receptor status, occurring only in estrogen receptor-α (ER-α) positive tumors [79] . These tumors generally are increase resistance to cisplatin [88] . A similar study using transfected MCF-7 cells gave a 3-fold increase in resistance to doxorubicin in the presence of wild-type p53 [89] . The same group also studied patient responses to doxorubicin and doxorubicin-combination therapy. Patients having MDM2-positive tumors had lower rates of complete and partial responses after receiving the drug than did those with MDM2-negative tumors [89] . In neuroblastoma cells, high levels of MDM2 led to an increase in the degradation of p53 and resulted in resistance to etoposide-induced apoptosis [90] . Another group studying neuroblastoma cells documented that loss of p53, including loss by MDM2-induced degradation, resulted in high-level drug resistance to melphalan (L-PAM) [91] .
cancers, where HER-2 is overexpressed in an estimated 30% of tumors [97] . MDM2 may also increase expression of the NF-κB (p65) transcription factor. One group noted that this type of induction overcame the pro-apoptotic effects of p53, leading to resistance to doxorubicin [98] . Thus, there are many possible p53-dependent and -independent mechanisms of action for the MDM2-mediated resistance to radiation therapy and chemotherapy. To confirm this hypothesis, we have recently used antisense or small interfering RNA (siRNA) to knock down MDM2 expression and have demonstrated that inhibition of MDM2 resulted in chemosensitization and radiosensitization in various human cancer models [99] . The therapeutic effects of MDM2 antisense inhibitors were seen in tumors containing wild type p53, mutant p53, or no p53 expression [99, 100] . Various other cancers expressing MDM2 have increased resistance to treatment. One group evaluated the response of 107 patients undergoing surgical resection and adjuvant chemotherapy for esophageal squamous cell carcinoma. They found that MDM2 expression correlated with shorter survival for patients undergoing post-operative chemo-or radiotherapy [60] .
OVEREXPRESSION OF MDM2 WITH OTHER MOLECULES
As can be read in other articles within this journal, MDM2 interacts with a number of cell cycle regulatory molecules, through both p53-dependent and -independent pathways. MDM2 remains oncogenic in p53-null cell lines and animal models, a fact that emphasizes its central role in tumorigenesis, regardless of p53 status [99] [100] [101] [102] . Various genes within a given tumor may be mutated, and tumors often acquire multiple mutations as they progress. MDM2 and p53 are only infrequently mutated within the same tumor [2, 8] , and, although wild-type p53 increases MDM2 expression, many p53 mutants do not [26, 103, 75, 104] . Thus the interaction of MDM2 with other molecules may be very important. MDM2 participates in a negative feedback loop with p53. It may also fulfill a negative regulatory function for other molecules, such as E2F1, pRb, p14/p19 ARF , p21, p63 and p73, ribosomal proteins, MDMX, and likely the estrogen, androgen and glucocorticoid receptors [55, 79, 99, [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] . Thus the roles of MDM2 are many and complex, and concurrent expression of MDM2 with other mutant or overexpressed regulatory molecules complicates the process of discerning the precise roles of MDM2. Sorting out the order of acquisition of the mutations and amplifications may allow for earlier diagnosis and better classification and staging of disease, and therefore, better treatment and prognosis.
Although there are many reports of MDM2 expression being related to a worse response to treatment, there have been a few that contradict these results. Rotterud and colleagues noted no significant role for MDM2 in the radioresistance of tumors in 59 patients with transitional cell carcinoma of the bladder [92] . Another study of colorectal cancer samples found no correlation between MDM2 expression and the response to chemotherapy [93] . Additionally, one group discovered that, for advanced breast cancer, high levels of MDM2 corresponded to a better response to treatment and longer time to progression [94] . These findings may be due to small sample size and variations in analysis of response, progression and survival.
Several mechanisms have been proposed for how MDM2 decreases the therapeutic benefits of cytotoxic drugs and radiation. The most obvious explanation is the role that MDM2 plays in p53 degradation. Because p53 is upregulated by DNA-damaging agents, including chemotherapy and radiation, the level of MDM2 is increased as a result of its role in feedback control. As a result, p53 degradation increases, preventing cell cycle arrest and apoptosis.
Another possible role for MDM2 in decreasing the response to chemotherapy is the multidrug resistance (mdr) gene. One study of the U87-MG glioblastoma cell line found that MDM2 increased expression of the mdr1 gene. This combination of increased mdr1 and heightened MDM2 expression led to decreased induction of apoptotic cell death by etoposide or doxorubicin [95] . A later study confirmed that mdr1 gene expression was increased by MDM2, and the resulting resistance to vincristine, etoposide and doxorubicin was reversible upon administration of an MDR modulator [88] .
As a general rule, co-overexpresion of mutant p53 with MDM2 correlates with a worse prognosis. In oral squamous cell carcinoma, combined expression of p53 and MDM2 was associated with a higher proliferation rate of the tumor [111] . Other studies, involving squamous cell carcinoma of the lung and colorectal carcinoma, showed that co-expression of p53 and MDM2 was associated with increased lymph node metastases [118, 119] . Examination of 78 samples of papillary carcinoma of the thyroid showed that p53 overexpression was, not surprisingly, linked to overexpression of MDM2. This overexpression correlated with larger tumor size [120] . In addition to correlating with worse prognosis and increased metastasis, co-expression of mutant p53 and MDM2 also was associated with more aggressive tumors [121] . The relative risk for death caused by soft tissue sarcomas was higher for patients with MDM2+/p53+ tumors than the additive risk from each factor alone [122] . Expression of both molecules also was associated with a higher risk of relapse [74] . Increased Several other mechanisms of action for MDM2-related resistance have been proposed. HER-2/neu (c-erbB-2) overexpression also can make cells resistant to apoptosis. One study showed that HER-2 resistance may depend indirectly on MDM2. HER-2 activates Akt, which in turn activates MDM2, increasing the degradation of p53 and the resistance to chemotherapy and radiation [95] . This mechanism is especially important for breast and ovarian expression of p53 and MDM2 can be correlated to decreased expression of ER-α and the pro-apoptotic Bax protein [55] , both of which are indicative of a worse prognosis and decreased response to conventional cancer therapies. However, there have been a few reports that did not support these findings. One study of transitional cell carcinoma of the bladder found that co-expression of p53 and MDM2 was predictive for a better prognosis for stage T2-T4 invasive tumors [42] . In addition, a few studies did not find a correlation between p53 and MDM2 expression and any prognostic factor [77, 122, 123] .
that regulates cell cycle phase transition, likely through interactions with both p53 and MDM2 [106] . Thus, MDM2 participates in yet another layer of control over cell cycle progression.
MDM2 may also interact with a variety of other molecules, including the estrogen, androgen and glucocorticoid receptors. A study in breast carcinoma found that overexpression of MDM2 correlated with increased expression of ER-α protein, and that MDM2 overexpression was associated with a better prognosis [79] . In contrast, coexpression of MDM2 and p53 may decrease ER-α [55] . However, MDM2 increases degradation of p53 by acting as its E3 ligase, targeting it for degradation by the proteasome. The protein may act similarly for the estrogen, androgen and glucocorticoid receptors, influencing their stability by increasing their ubiquitination [116, 117] . Activation of the ER may also stimulate increased MDM2 synthesis, leading to increased degradation of both the ER and p53 [116] . Analogous to the ER, the glucocorticoid receptor and androgen receptor also seem to be targets of MDM2-mediated regulation [117] . This level of control is likely to be important in a number of cancers, particularly breast and prostate carcinomas, as well as for other diseases, especially those affecting the immune system. There are probably other molecules that interact with MDM2; their identification could help explain more about the oncogenicity of MDM2.
Co-expression with other molecules has not been evaluated as thoroughly as with mutant p53. When coexpression of p21 with MDM2 is examined, decreased expression of p21 is associated with a worse prognosis. Studies using breast and colorectal tumors revealed that those positive for MDM2, p53 and p21, or MDM2, bcl-2 and p21 had a more favorable prognosis than those with decreased p21 [58, 110] . Conversely, a study of oral squamous cell carcinomas showed that tumors positive for p53, MDM2 and p21 had a poorer clinical outcome [111] . Thus, more work needs to be done to determine what role the co-expression plays. We recently showed that MDM2 is a negative regulator of p21, promoting its proteasomal degradation [100] . Thus, it is likely that tumors overexpressing MDM2 would have lower p21 expression. A tumor staining positive for both may be indicative of mutations to one or both of the proteins.
Overall, it seems that MDM2 amplification and overexpression, alone or in combination with other proteins, negatively impact the survival of cancer patients. Despite the occasional report that MDM2 expression can correlate with a favorable outcome, there are many more showing that MDM2 has deleterious effects on the patient response to therapy, remission rate, metastatic rate, and survival.
When evaluating the role of MDM2 in cancer prognosis, one should take into account the interaction between MDM2 and p14/p19 ARF . MDM2 and p14 have a direct interaction, which inhibits the MDM2-induced degradation of p53 [125, 126] . Because of this interaction, the loss of p14 can lead to decreased apoptosis, resulting in a poorer prognosis. The interaction can also give rise to co-expression of p14 and MDM2 because the more stable p53 leads to increased MDM2 transcription. When MDM2 is overexpressed with a ratio of more than 1:1 with p14, there is a correlation with a higher grade tumor phenotype [109] . Since Her-2/erbB2 may also regulate both MDM2 and p14 by directing their localization, it may be necessary to evaluate multiple markers to correctly gauge the prognosis of a particular cancer [81] .
MDM2 IN OTHER DISEASES
Although cancer is the main focus of research on MDM2, this protein is also involved in other diseases. That MDM2 has such a role is not surprising, considering its involvement in so many different cell processes. Similar to the adverse effects of MDM2 overexpression for cancer patients, MDM2 likewise seems to be involved in the pathogenicity of HIV. HIV-1 infection upregulates the expression of MDM2 [129] , and anti-HIV drugs decrease its expression [130] . MDM2 interacts with Tat, functioning as an E3 ligase, resulting in ubiquitination of the Tat protein.
Tat requires non-degradative ubiquitination in order to activate the transcription of the long terminal repeat (LRT) of HIV [131] . Thus, upregulation of MDM2 leads to increased viral replication. MDM2 is also increased by the Kaposi's sarcoma virus, which is associated with AIDS infection. The sarcoma virus increases the level of p53, likely by decreasing the MDM2-p53 interaction. The increase in MDM2, however, is not solely due to the increase in p53. MDM2 expression is increased in p53 null cells as well, suggesting that the increase in MDM2 is p53-independent [132] . This increase in MDM2 may underlie part of the oncogenic potential of the virus.
MDM2 interacts with the retinoblastoma protein (pRb) as well, preventing pRB from accomplishing its function in G1 cell cycle arrest [127] . A study on expression of pRb and MDM2 in soft tissue sarcomas showed that tumors overexpressing pRb were also more likely to show immunopositivity for MDM2. Patients with tumors staining positive for both pRb and MDM2 had higher risk and a poorer prognosis than patients with overexpression of neither or only one factor [107] . In studies of non-small-cell lung cancer (NSCLC), abnormal expression of pRb was frequently associated with overexpression of p53 and MDM2. Up to 27% of NSCLC expressed this combination (abnormal pRb, overexpressed p53 and MDM2), and these tumors had a higher proliferation index, lower apoptotic index and an increased tendency to aneuploidy compared to tumors with normal expression [108, 128] . The same group also noted that E2F-1 expression was increased in the pRB/p53/MDM2 (abnormal/+/+) tumors [105] . E2F-1 is a transcription factor MDM2 is overexpressed in Epstein-Barr virus (EBV)-infected cells [133] and the protein may be overexpressed upon human papilloma virus (HPV) infection [134] . During HPV infection, the E6 protein downregulates p53, perhaps leaving the pool of MDM2 to interact with its non-p53 signaling partners [135] [136] [137] . MDM2 may also exacerbate other disease states. In an in vivo model of hemophilic synovitis I, a genetic disorder caused by a deficiency in blood coagulation factors, there is an eight-fold increase in MDM2 mRNA. This increase may be caused by iron from blood leaking into joints. The authors hypothesize that MDM2 may be responsible for the decreased apoptosis or increased cell proliferation within the joints, causing inflammation and the debilitating effects of the resultant arthritis [138] .
processes, and may allow more specific and effective treatments to be tailored to the individual cancers.
VARIATIONS IN THE EVALUATION OF MDM2 EXPRESSION AND IMPACT ON DATA ANALYSIS AND INTERPRETATION
The different methods used for evaluation may be part of the reason that contradictory results have been obtained about the clinical implications of MDM2 expression and overexpression. Most of the studies reviewed by Zhang and Wang [2] and Momand et al. [8] examined gene amplification, usually determined by CGH (comparative genomic hybridization), Southern blots, FISH (fluorescence in situ hybridization), PCR-SSCP (polymerase chain reaction-single strand conformation polymorphism), or differential PCR, all of which have variable degrees of accuracy and repeatability. However, there was no standard for what was to be considered overexpression, and many studies did not specify where they drew the line for what they called normal versus over-expression. Some of the older studies and most of the newer (since 2000) studies of gene expression make a point to explain what they call overexpression (usually 2-10-fold normal levels), although there is still no standard to differentiate normal versus overexpression. Some of the newer studies, accomplished with microarrays, do not consider a change to be relevant until there is at least a 2-fold difference from normal.
MDM2 EXPRESSION AS A DIAGNOSTIC TOOL
MDM2 may also be useful as a diagnostic tool or as a marker, particularly for tumor stage or grade. In many cases, MDM2 expression is a marker for advanced stage or highgrade tumors. For bladder carcinoma, non-Hodgkin's lymphoma, prostate carcinoma, testicular germ cell tumors and perhaps soft tissue sarcomas, MDM2 expression correlates with larger, more aggressive tumors [78, 21, 37-39, 82, 65, 16] . As with the prognostic indications, there are conflicting reports as to which tumor stage has the highest levels of MDM2. Some studies have found that MDM2 expression correlates with lower-grade tumors. For example, in leukemia, brain tumors, and soft tissue sarcoma, there is higher MDM2 expression in low-grade tumors than in advanced stage disease [41, 20, 69, 71] . Some of these apparently conflicting results may be due to the methods used, but they may also reflect differences between sub-types of cancer, for example rhabdomyosarcoma versus liposarcoma, or glioblastoma versus astrocytoma.
Recent studies have often examined the mRNA level using RT-Q-PCR (real-time quantitative PCR) or Northern blots. Since specific and effective antibodies exist for MDM2, most of the studies being accomplished now examine protein expression, typically by IHC (immunohistochemistry) or Western blots. It is also necessary to differentiate between nuclear and cytoplasmic MDM2. Similarly, evaluating the level of protein expression may be a more realistic approach to analyzing the level of MDM2 and relating the level to its effects on the tumor. Even more effective would be an evaluation of the functional MDM2 protein, including differentiation between different splice forms and phosphorylation and ubiquitination states.
Likewise, measurement of MDM2 expression may help to differentiate similar cancer types. In glioblastoma, there is a difference in MDM2 gene expression between primary (de novo) and secondary (developed from low-grade astrocytoma) glioblastomas. About 7% of primary glioblastomas have amplified MDM2 gene expression, whereas secondary glioblastomas have none [26] . MDM2 expression can also be used to differentiate liposarcoma subtypes. More than 90% of retroperitoneal liposarcomas express MDM2 protein, while less than half of non-retroperitoneal liposarcomas have an MDM2 positive phenotype, and none of the myxoid liposarcomas express the oncoprotein [139] . Another group noted differences in MDM2 gene expression between different types of sarcomas. They saw different amplification levels in osteosarcomas, liposarcomas, lipomas and malignant fibrous histiocytomas, perhaps making a test for MDM2 expression a useful complement to standard histological and pathological examinations. Ouban and colleagues found a difference in MDM2 expression levels between the rare verrucous carcinoma (VC) and more common squamous cell carcinoma (SCC) of the penis. Almost 80% of VC tumors stained positive for MDM2, while less than 20% of SCC tumors showed this phenotype. The location and intensity of staining also varied between the cancer types [140] . Another group investigating testicular germ cell tumors also saw differences between tumor types. MDM2 staining was noted in 93% of embryonal carcinomas and 47% of seminomas, but in only 7% of intratubular germ cell neoplasia [17] . These differences may be related to distinct pathogenic With IHC, and to a lesser extent with the mRNA and DNA, there may be uncertainties depending on how much of the tumor was analyzed. While some groups utilized multiple tumor sections from the same sample, many studies evaluated only a section of the tumor for MDM2 expression. Because tumors are heterogeneous, the expression level of MDM2 may vary even within different sections of the tumor. Thus the entire tumor must be homogenized (for mRNA/DNA and Western Blots) or several random sections must be stained and compared (by IHC) in order for the expression level to be representative of that tumor. Additionally, since tumors from different patients vary somewhat in their expression level, a large number of samples are needed to form an accurate picture of the amount of expression typical for that type of cancer. For highincidence cancers, such as breast and prostate carcinoma, obtaining samples is less of an obstacle than for uncommon cancers, such as renal cell or Wilm's tumors. It is difficult to evaluate precisely the expression level in uncommon cancers simply due to the lack of samples available. Other factors must also be taken into account when evaluating the effects of MDM2 expression, such as concomitant disease, previous treatment(s), and the stage and location of tumor(s).
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CONCLUSION
Because of its prevalent overexpression and the role it plays in cell cycle regulatory pathways, MDM2 appears to be a molecule central to the control of cancer development, growth and progression. MDM2 is overexpressed in most types of cancer from various tissues. Despite the sometimes conflicting results from studies, the overall trend from a wide variety of tumors is that MDM2 expression is associated with decreased overall survival, increased recurrence, increased metastasis and decreased response to therapeutic intervention, indicating that MDM2 can be an excellent target for cancer therapy.
ABBREVIATIONS
ALL/AML= acute lymphoblastic leukemia/acute myeloid leukemia CLL/CML= chronic lymphocytic leukemia/chronic myeloid leukemia FISH = fluorescence in situ hybridization IHC = immunohistochemistry In tumors expressing wild type p53, inhibition of MDM2 expression will stabilize p53 and allow it to perform its pro-apoptotic function, while simultaneously preventing MDM2 from exerting its p53-independent oncogenic effects. A number of different strategies are being utilized in an effort to block or re-route the action of MDM2. These strategies encompass the latest and most innovative molecular biology strategies including antisense oligonucleotides [89, 100, [141] [142] [143] [144] [145] , small molecule or peptide inhibitors [146] [147] [148] , ribozymes [149] , RNA interference [150] , gene therapy [151] [152] [153] , and attenuated viral infection to decrease mutant p53 expression [154] [155] [156] . Each approach has advantages and drawbacks, but the ongoing research will aid in the pursuit of knowledge not only about the exact functions of MDM2, but also may yield a clinically useful molecule. Considering the multiple functions of MDM2, inhibiting MDM2 expression may represent the best strategy to prevent MDM2 from functioning as an oncogene. Targeting an individual interaction, e.g., that between MDM2 and p53, may have limited effects due to other pathways of MDM2 action. Interested readers are directed to other reviews in this issue of Current Cancer Drug Targets.
MDM2
= Currently, there are no anti-MDM2 drugs in clinical trials, but there are three ribozyme drugs and more than 20 antisense oligonucleotides currently undergoing clinical testing to block expression of other relevant molecules [157] . There have been clinical trials of gene therapy for p53, but most have been disappointing [158, 159] . Antisense oligonucleotides, and perhaps RNA interference, are the most promising strategies for future therapeutic applications. Preclinical studies using antisense oligonucleotides have shown promise for several types of cancer by increasing the sensitivity to radio-and chemotherapy and by causing direct anti-tumorigenic effects [99, 100, [142] [143] [144] [145] . Thus, although it seems that there is no MDM2-related treatment to be applied in the immediate future, it is likely that therapies targeting the oncoprotein will eventually be used clinically. This should lead to an improvement in patient survival by decreasing chemo-and radio-resistance and by reducing metastasis. 
